Coverage

Pharma & biotech

KOLs, former regulators, and clinical investigators who've been inside the therapeutic area you're studying, not adjacent to it.

Scientist working with pipette and test tubes in a lab

Expert types

Key opinion leaders (KOLs)Former FDA / EMA reviewersClinical investigatorsCommercial & brand leadsMedical affairs veterans

Common use cases

Pipeline & mechanism diligence

Validate a therapeutic mechanism or competitive pipeline read with practicing specialists in the relevant indication.

Regulatory pathway assessment

Get a former reviewer's perspective on approval strategy, trial design, or likely agency questions.

Launch readiness

Stress-test commercial and access assumptions with brand leads who've run comparable launches.

Competitive positioning

Understand how prescribers actually weigh your asset against the standard of care.

Questions we help answer

Sample transcript excerpts
Q1

How will oncologists actually sequence this drug relative to the current standard of care?

Q2

What would make the FDA push back on this trial design, based on precedent?

Q3

Is the KOL enthusiasm at conferences translating into real prescribing intent?

Q4

What did the competitor's Phase 2 readout actually tell prescribers, versus what the press release said?

In practice

An investor needed to know whether oncologists would really switch regimens on a competitor's Phase 2 readout, or whether the market was overreacting to a press release. We sourced three practicing oncologists across academic and community settings within three business days, scoped around prescribing behavior rather than trial mechanics, and came back with a split view by practice setting that looked nothing like the market's first reaction.

Composite example, illustrative only.